bs_bs_banner Convenor s Welcome 1 Convenor s Welcome

Transcription

1 bs_bs_banner Convenor s Welcome 1 Convenor s Welcome Welcome to the 2013 Annual Scientific Meeting (ASM) of the Medical Oncology Group of Australia Incorporated (MOGA), Blood, Biomarkers and Beyond. Our aim in developing a scientific program for this year s ASM was to focus on important, current research, clinical and professional oncology issues around biomarkers. Biomarkers are likely to play a pivotal role in the routine management of patients with cancer and guide drug development in this era of targeted therapy. This year s meeting provides practical information about biomarkers as tools for screening, diagnosis and treatment; translational biomarker issues; and practical aspects of biomarker development, including future applications in translational research, drug development, research and clinical practice. Five distinguished international guest speakers are contributing to the meeting program including Professor Allen Chan (Hong Kong), Professor Mark J. Ratain (United States of America), Professor Caroline Robert (France), Professor Amit M. Oza (Canada) and Professor Kazuo Tamura, President of the Japanese Society of Medical Oncology (JSMO). Professor Hirotoshi Akita, Education Committee Chair, for JSMO will be an international guest speaker for the Best of ASCO program. This international contingent is supplemented by more than 23 Australian expert speakers and chairs. The scope of the scientific program of course, in keeping with our chosen theme, extends well beyond biomarkers, to include sessions on circulating tumours and stem cells; proteomics; next gen sequencing: plasma DNA; genomics; and an update on the 2015 Study. Satellite sessions include two industry symposia, the first on Barriers to Access to Oncology Medicines in Australia and, the second on, Making Targeted Therapy possible for Ovarian Cancer with international guest speaker Professor Amit M. Oza. Additional tumour specific sessions and foci have also been incorporated covering melanoma, lung, prostate, ovarian and gynaecological cancers, cancers of the unknown primary and ATCLL. Professor Caroline Robert from the Institute Gustave Roussy, in France will join with our distinguished colleagues, Dr Georgina Long and Professor Grant MacArthur to present a session on developments in melanoma research and clinical practice that will be one of many program highlights. A viewpoint session considers, Who pays for high costs drugs? While the Asia Pacific Perspectives session, provides a rare opportunity to examine medical oncology research and practice from the perspectives of Japan, Hong Kong and Australia, with the aim of building regional networks. The scientific program also showcases Australian medical oncology research in Best of the Best Research 2013 and Consultant and Trainee Oral Presentation sessions. These are complemented by a large poster exhibition and the Amgen Australia Awards. For Australian medical oncology trainees the program includes a Trainees Education Program with its focus on rare tumours, Communication Skills Training sessions on Transition to Palliation and, many other relevant ASM sessions. MOGA also welcomes to the ASM our members, Professor Frances Boyle and Dr Mustafa Khasraw who will be presenting an update on Guidelines for Brain Metastases in Breast Cancer they are developing for Cancer Australia; Professor Michael Green who is convening a national Consensus Meeting: on Guideline Development for Safe Handling of Monoclonal Antibodies; and Associate Professor Jacquie Chirgwin who is chairing a focus group for the development of a Cancer Treatment App. I thank and acknowledge the contribution of the ASM Planning Committee in putting together an exceptional scientific and social program, that truly is inspiring in its scope and offers something for everyone; and, the many MOGA members who have assisted with planning, chairing and presenting sessions. On behalf of the ASM Planning Committee I welcome you to Melbourne and hope you take the time to enjoy its many delights. We trust that this year s ASM will prove to be an enriching and rewarding experience for all our delegates, speakers and professional colleagues. Dr Yoland Antill

2 2 MOGA Annual Scientific Meeting Organising Committee Dr Yoland Antill, Convenor MOGA ASM 2013 Medical Oncologist, Cabrini Health, Melbourne Associate Professor Gary Richardson Director of Oncology Clinics Victoria, Melbourne Director of Cabrini Academic Haematology and Oncology Service, Melbourne Chairman, Medical Oncology Group of Australia Incorporated Associate Professor Michael Michael Chair of Upper Gastrointestinal Cancer Service,, Melbourne Associate Professor Benjamin Solomon Medical Oncologist,, Melbourne Dr Andrew Haydon Medical Oncologist, The Alfred Hospital, Melbourne Dr Tess Schenberg MOGA National Advanced Trainee Representative The Alfred Hospital, Melbourne Ms Kay Francis Executive Officer, Medical Oncology Group of Australia Incorporated Ms Cristina Dietmann Event Manager, Medical Oncology Group of Australia Incorporated

3 Medical Oncology Group of Australia-Executive Committee 3 Medical Oncology Group of Australia-Executive Committee Chairman Associate Professor Gary Richardson, Cabrini Hospital, Malvern, Melbourne Deputy Chairman Dr Rosemary Harrup, Royal Hobart Hospital, Tasmania Honorary Treasurer Dr Christopher Steer, Border Medical Oncology, Wodonga, Victoria Past Chairman Associate Professor Michael Michael,, Melbourne Executive Members Dr Diana Adams, Macarthur Cancer Therapy Centre, Campbelltown Hospital, Sydney Professor Joanna Dewar, Sir Charles Gairdner Hospital, Perth Dr Deme Karikios, National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney Associate Professor Linda Mileshkin,, Melbourne Dr Catherine Shannon, Mater Adult Hospital, Brisbane Dr Brian Stein, Adelaide Cancer Centre, South Australia National Advanced Trainee Representative Dr Tess Schenberg, The Alfred Hospital, Melbourne

4 4 MOGA Annual Scientific Meeting Acknowledgements PLATINUM SPONSOR GOLD SPONSORS TRAINEE TRAVEL AWARDS SPONSOR SILVER SPONSOR MEDICAL ONCOLOGY TRAINEE DINNER ABSTRACT & POSTER AWARD SPONSOR

5 Acknowledgements 5 POSTER WALK AND TALK SPONSOR BRONZE SPONSORS DAY IN REVIEW AND APP SPONSOR INDUSTRY SYMPOSIUM 2 SPONSOR COMMUNICATION HUB SPONSOR

6 6 MOGA Annual Scientific Meeting NOTEPAD AND PEN SPONSOR CANCER ACHIEVEMENT AWARD SPONSOR COMMUNICATION SKILLS TRAINING PROGRAM SPONSOR EXHIBITORS

7 Acknowledgements 7

8 8 MOGA Annual Scientific Meeting Melbourne Convention Centre Floor Plan

9 Exhibition Floor Plan 9 Exhibition Floor Plan

10 10 MOGA Annual Scientific Meeting Exhibitor Listing Amgen Oncology 34 Aspen Australia 36 AstraZeneca 33 Bayer Australia 3 Boehringer Ingelheim 22, 23, 28 & 29 Caris Life Sciences 20 Elekta 21 Eli Lilly Australia 6 & 7 GlaxoSmithKline 37 & 38 Healthcare at Home Australia 9 Healthscope Advanced Pathology 25 Ipsen 1 Janssen Cilag 24 mdbriefcase Free Accredited ecpd 35 Merck Serono 19 MSD 4 Novartis Oncology 32 Pfizer Oncology 2 Pierre Fabre Medicament Australia 26 Roche Products 27 Sanofi 30 & 31 Sapphire Bioscience Pty 8 Sirtex Medical Products 39 Specialised Therapeutics Australia 40

11 Speakers Overview 11 Speakers Overview INTERNATIONAL Professor Allen Chan Professor of Chemical Pathology The Chinese University of Hong Kong Prince of Wales Hospital New Territories, Hong Kong Professor Amit M. Oza Professor of Medicine The University of Toronto Director, Clinical Cancer Research Program Co-Director, Robert and Maggie Bras Family Drug Development Program Princess Margaret Hospital Toronto, Canada Professor Mark J. Ratain Leon O. Jacobson Professor of Medicine Director, Center for Personalized Therapeutics Associate Director for Clinical Sciences, Comprehensive Cancer Center The University of Chicago Chicago, United States of America Professor Caroline Robert Professor of Dermatology Head, Dermatology Unit Institute Gustave-Roussy Villejuif Cedex, France Professor Kazuo Tamura Professor of Medicine, Division of Medical Oncology, Haematology and Infectious Diseases Fukuoka University Fukuoka, Japan President, Japanese Society of Medical Oncology BEST OF ASCO INTERNATIONAL SPEAKER Professor Hirotoshi Akita Chief, Department of Medical Oncology Hokkaido University Hospital Professor, Department of Medical Oncology Hokkaido University Graduate School of Medicine Sapporo, Japan NATIONAL Professor David Bowtell Head, Cancer Genomics and Genetics Program Principal Investigator, Australian Ovarian Cancer Study Department of Pathology and Department of Biochemistry The University of Melbourne Professor Stephen Clarke AOM Professor of Medicine, Northern Clinical School ANZC Research Institute Royal North Shore Hospital The University of Sydney Sydney, New South Wales Mr Stuart Giles Chairman, Icon Cancer Care Managing Partner, Executive Chairman APHS Pharmacy Brisbane, Queensland Professor Sean M. Grimmond Director, Queensland Centre for Medical Genomics Institute for Molecular Bioscience The University of Queensland Brisbane, Queensland

12 12 MOGA Annual Scientific Meeting Dr Suzanne Hill Chair, Pharmaceutical Benefits Advisory Committee Canberra, Australian Capital Territory Associate Professor Lisa Horvath Head, Department of Medical Oncology Royal Prince Alfred Hospital Central Clinical School of Medicine The University of Sydney Sydney, New South Wales Dr Mustafa Khasraw Andrew Love Cancer Centre, Geelong and Royal Melbourne Hospitals Associate Professor Matthew Links St George Hospital Associate Professor, University of New South Wales Sydney, New South Wales Dr Sherene Loi Group Leader, Translational Breast Cancer Genomics Laboratory Dr Georgina Long Medical Oncologist Clinical Researcher Melanoma Institute Australia University of Sydney Sydney, New South Wales Associate Professor Michael MacManus Consultant Radiation Oncologist Associate Director (Research), Department of Radiation Oncology Professor Grant McArthur Head, Translational Research Group Head, Molecular Oncology Laboratory Associate Professor Joe McKendrick Director, Oncology, Haematology and Palliative Care Box Hill Hospital Associate Professor Michael Michael Director, Upper GI Oncology Service Co-Chair, Neuroendocrine Unit Associate Professor of Medicine The University of Melbourne Associate Professor Linda Mileshkin Department of Medical Oncology and Haematology Mercy Hospital for Women Associate Professor Sandra O Toole Head, Molecular Diagnostic Oncology Royal Prince Alfred Hospital Co-Director, Translational Breast Oncology The Kinghorn Cancer Centre Garvan Institute of Medical Research Sydney, New South Wales Associate Professor Gary Richardson Director, Oncology Clinics Victoria Director, Cabrini Academic Haematology and Oncology Services

13 Speakers Overview 13 Associate Professor Clare Scott Royal Melbourne Hospital Royal Women s Hospital Laboratory Head, Molecular Genetics of Cancer Division Walter & Eliza Hall Institute of Medical Research Associate Professor David Thomas Research Fellow, National Health Medical Research Council and Victorian Cancer Agency Senior Research Fellow, University of Melbourne

14 14 MOGA Annual Scientific Meeting International Speakers Professor Hirotoshi Akita is professor of the Department of Medical Oncology at Hokkaido University Graduate School of Medicine in Sapporo, Japan. He is also Professor and Chief of the Department of Medical Oncology at Hokkaido University Hospital. Professor Akita graduated from Hokkaido University School of Medicine in 1981 and the Hokkaido University Graduate School of Medicine in He was a Fogarty Visiting Fellow from 1987 to 1990 at the National Cancer Institute-Navy Medical Oncology Branch in the United States of America. After he returned to Japan, he worked as Assistant Professor at the Hokkaido University Hospital in the Lung Cancer Unit of Respiratory Medicine from 1990 to Professor Akita has been a Professor of the Department of Medical Oncology at Hokkaido University Graduate School of Medicine since Professor Akita s major interests include translational and clinical research on the treatment of solid tumours, with a focus on lung cancer. He is also interested in biomarkers and companion diagnostics for individualised cancer therapy. He has published more than 120 peer-reviewed English papers, including papers in Cancer Research and Clinical Cancer Research. Professor Akita has represented many domestic academic societies. He is the current Chair of the Education Committee of the Japanese Society of Medical Oncology (JSMO) and is the incoming President for the 13th Annual Meeting of JSMO to be held in July Professor Akita has also served as a Director of JSMO, the Japan Lung Cancer Society, and the Japanese Society of Clinical Cytology. He is a member of ASCO, AACR, and IASLC. Professor Allen Chan is professor of chemical pathology at the Chinese University of Hong Kong. His main research interest is the development of new diagnostic tests based on the analysis of circulating cell-free nucleic acids. The clinical applications of these tests cover different areas including oncology, prenatal diagnosis, organ transplantation and trauma. With these inventions, he currently holds more than 20 international patents/patent applications. A number of these molecular tests, for example the noninvasive prenatal testing for Down syndrome and Epstein-Barr virus DNA test for nasopharyngeal carcinoma, have already been offered as routine clinical tests in many different parts of the world. Professor Chan has received numerous research awards, including the 2007 Best Research Presentation Award from the Hong Kong College of Pathologists, the 2007 Best Original Research Award from the Hong Kong Academy of Medicine, and the 2007 Sigi Ziering Award from the American Association of Clinical Chemistry. Professor Chan is also an enthusiastic teacher and has received a total of four Teacher of the Year Award from the Faculty of Medicine of the Chinese University of Hong Kong. Professor Chan graduated from the medical school of the University of Hong Kong in After his graduation, he received training in internal medicine and obtained Fellowship of the Royal College of Physicians in After four years training in gastroenterology, he left the specialty of internal medicine and joined the Chinese University of Hong Kong to pursue his PhD training in molecular biology under the supervision of Professor Dennis Lo. Later, he also obtained Fellowships of the Royal College of Pathologists of Australasia and the Hong Kong College of Pathologists. Professor Amit M. Oza is a senior staff physician and professor of medicine at Princess Margaret Hospital, Toronto. He graduated from St. Bartholomew s Hospital, University of London (United Kingdom (UK)) and completed his internal medicine and medical oncology training in the UK. He completed Clinical Research Fellowships at St. Bartholomew s Hospital (Imperial Cancer Research Fund), Princess Margaret Hospital, Toronto and at the Netherlands Cancer Institute, Amsterdam. He is a Fellow of the Royal College of Physicians of London and Canada. Professor Oza has been the Principal Investigator (PI) and program scientific lead for the Princess Margaret Hospital Consortium over the last six years. He has been an active PI and co-investigator in phase I, II, and III trials for gynaecological cancer and advanced

15 International Speakers 15 colorectal malignancies. His research interests are focused on the development, assessment and validation of novel therapeutic strategies for cancer including molecular targeted therapies. Many of these studies also incorporate novel endpoints and translational research, which are developed in close relationship with scientists and pathologists at the Ontario Cancer Institute and the Princess Margaret Cancer Centre. He is the principal and co-author of more than one hundred and thirty publications in major peer-reviewed journals such as the New England Journal of Medicine, Lancet Oncology, Cancer Research, Journal of Clinical Oncology, Annals of Oncology, Investigational New Drugs and Clinical Cancer Research. He is also head of the Cancer Centre s Clinical Research Program and, Co-Director of the Robert and Maggie Bras and Family Drug Development Program at Princess Margaret Hospital. Professor Mark J. Ratain is a haematologist, oncologist and clinical pharmacologist with significant experience in early clinical trials and pharmacogenomics of anticancer agents. His activities include both University of Chicago and multiinstitution research efforts. He has been Principal Investigator (PI) of the University of Chicago Phase I grant (Phase I Clinical Trials of Anticancer Agents) funded by the National Cancer Institute (NCI) since 1989, and PI for the Clinical Therapeutics training grant since He was the PI of the National Institutes of Health (NIH)-funded U01 Pharmacogenetics of Anticancer Agents Research (PAAR) Group for ten years, and has continued as co-pi since 2010 (now named PAAR-Pharmacogenomics of Anticancer Agents Research Group). Professor Ratain served as the first chair of the Steering Committee of the NIH Pharmacogenetics Research Network, as well as one of the first co-chairs of the NCI Investigational Drug Steering Committee and now serves as co-chair of the Clinical Trials Design Task Force. He also led the Cancer and Leukemia Group B Pharmacology and Experimental Therapeutics Committee from , and now leads its successor, the Alliance for Clinical Trials Pharmacogenomics and Population Pharmacology Committee. Since 1993, he has also served as Senior Scholar for The Center for Clinical Medicine Ethics. He has received multiple honours for his work in oncology and clinical pharmacology, including the Emil J. Freireich Award for Clinical Research (MD Anderson, 2008), the Institute for Pharmacogenomics and Individualized Therapy Clinical Service Award (University of North Carolina, 2008), the Research Achievement Award in Clinical Pharmacology and Translational Research (American Association of Pharmaceutical Scientists, 2009), the Rawls-Palmer Progress in Medicine Award (American Society for Clinical Pharmacology and Therapeutics, 2010), the Henry T. Lynch Lectureship in Medical Genetics (NorthShore University Health System, 2010), the Robert Hart Waldman Lectureship (University of Nebraska Medical Center, 2011), the Translational Research Professorship (American Society of Clinical Oncology, 2011), Honorary Fellow (American College of Clinical Pharmacology, 2011), Visiting Professor (Food and Drug Administration, Center for Drug Evaluation and Research, Office of Clinical Pharmacology, 2012) and received Special Recognition (Department of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, University of Utah, 2012). Professor Caroline Robert is Head of the Dermatology Unit at the Institute Gustave-Roussy, Paris, France. Professor Robert gained her medical degree at the Cochin Port-Royal School of Medicine, Paris, in 1990, after which she was made a faculty member of the graduate school of biological sciences and received her French Board Certification in Dermatology in On gaining her certification, she was appointed Assistant Professor in Dermatology at the St-Louis Hospital, Paris. Professor Robert completed a research fellowship at Harvard, United States of America and a PhD in cancer immunology and immunotherapy. In 2000, she returned to Europe as Medical Director for Johnson & Johnson Consumer Europe. In 2001, she took a position at the Institut Gustave-Roussy as Assistant in Dermatology, before becoming Head of the Dermatology Unit in Professor Robert is a board member for the European Association of Onco-Dermatology, melanoma board secretary for the European Organization for the Research and Treatment of Cancer, a member of the European Association of Dermato-Venereology and the French society of Dermatology and Venereology. Professor Robert is a scientist of international renown in the clinical and translational research of melanoma and the cutaneous side-effects of new targeted chemotherapies. She has authored more than 120 articles in peer-reviewed scientific journals,

16 16 MOGA Annual Scientific Meeting including a number of publications on new treatments for metastatic melanoma and been involved in numerous international clinical trials. Professor Kazuo Tamura is a professor of medicine at Fukuoka University in the Division of Medical Oncology, Haematology and Infectious Diseases. He graduated from Kyushu University and completed his internship and residency in internal medicine at Elmhurst General and Mt. Sinai Hospital, in the United States of America (USA) in Professor Tamura completed a medical oncology Fellowship at Roswell Park Memorial Institute, in Buffalo, USA in After he returned to Japan, he worked as a clinical chief in the division of Haematology and Oncology at the Miyazaki Prefectural Hospital and in 1997 was appointed Professor of Medicine at Fukuoka University. Professor Tamura s major interests are lymphoma, breast cancer, supportive care and cancer education. He is a member of the Japanese Clinical Oncology Group and participates in many phase I-III studies. He has published 174 English and 310 Japanese papers. His English publications have been published in major peer-reviewed journals including the Journal of Clinical Oncology and Annals of Oncology. Professor Tamura has served as President of The Japanese Society of Medical Oncology (JSMO) since 2009, working on enhancing cancer patients quality of life, cancer research and education as well as strengthening the tie between JSMO and foreign societies especially in the Asian Pacific region. He is also a Committee member of the Cancer Management Action Plan at the Ministry of Health, Labour and Welfare, and the Cancer Professional Education Plan at the Ministry of Education, Culture, Sports, Science and Technology assisting in developing policy in cancer medicine in Japan.

17 National Speakers 17 National Speakers Professor David Bowtell, after ten years as Director of Research at the, Melbourne, returned to full time research in early He is Principal Investigator for the Australian Ovarian Cancer Study, one of the largest population-based cohort studies of ovarian cancer in the world, involving over 2000 women. Professor Bowtell s laboratory focuses on the genomic analysis of ovarian cancer and the genetic basis of treatment resistance, including investigation of CyclinE1 as a therapeutic target in high grade serous cancers. His work is part of the International Cancer Genome Consortium, an ambitious program to map the genomes of the 50 most common cancer types. Professor Stephen Clarke AOM is a medical oncologist and translational cancer researcher based at the University of Sydney in New South Wales, Australia. Professor Clarke obtained his medical degree (MB BS) through the University of Sydney in He completed an FRACP in Medical Oncology in 1990 at Royal North Shore Hospital in Sydney. From , Professor Clarke worked in the Drug Development Unit of the Institute of Cancer Research at the Royal Marsden Cancer Hospital in Sutton, Surrey, United Kingdom. He obtained a PhD in cancer pharmacology from the University of London and an MD from the University of Sydney in He returned to Australia in 1994, and worked at a number of cancer centres before returning to Royal North Shore Hospital in He has been involved in the assessment of predictors of outcome in patients with colorectal cancer and studies of cancer drug metabolism. In addition, his laboratory made major findings in relation to the impact of cancer associated inflammation on chemotherapy toxicity and survival. He has been an invited speaker at numerous national and international meetings and has over 200 publications in peer-reviewed journals. Since 2004, he has been a Professor of Medicine at the University of Sydney. He is the Oncology Adviser for the Australian Department of Veterans Affairs, and is a member of the Repatriation Pharmaceutical Reference Committee. In 2012, he was awarded an Order of Australia Medal in the Australia Day Honours and in 2013 was awarded the Eric Susman Prize of the Royal Australasian College of Physicians. Mr Stuart Giles is Chairman of Icon Cancer Care and Managing Partner and Executive Chairman of APHS Pharmacy, a national pharmacy service to hospital, oncology, aged care and community pharmacy sectors. He holds a Bachelor of Pharmacy and has more than 20 years experience in operating and transforming customer-centric healthcare organisations. Mr Giles was instrumental in the establishment of Integrated Clinical Oncology Network Pty Ltd, now operating as Icon Cancer Care, which was born out of an APHS Pharmacy strategy to establish a national, market-leading presence in the day oncology sector. Named a Regional Winner in 2010 Ernst & Young Entrepreneur of the Year, he brings an energetic and innovative approach to developing the commercial success of Icon Cancer Care, accompanied by an in-depth understanding of customer service and the pharmacy sector. Professor Sean Grimmond is the Director of the Queensland Centre for Medical Genomics, located at the Institute for Molecular Bioscience, The University of Queensland. He completed his PhD in Cancer Genetics in His postdoctoral research at Queensland Institute of Medical Research ( ) contributed to the positional cloning of the MEN1 tumour suppressor gene, and the cloning, molecular characterisation and commercialisation VEGFB endothelial Growth factor with AMRAD. In 1996, Sean was awarded a CJ Martin fellowship and pioneered expression analyses of gonadal organogenesis using shotgun cdna sequencing and microarray profiling at the MRC Mammalian Genetics Unit & Mouse Genome Sequencing Centre, United Kingdom. He returned to Australia and the Institute for Molecular Bioscience in The central focus of his research over the last decade has been to capture and interrogate transcriptome, genome

18 18 MOGA Annual Scientific Meeting and epigenome data from model systems and patient samples and define the underlying genetic network controlling key developmental processes and pathological states. Central to this has been continued efforts to pioneer genomic technologies for studying cancer and development (array-based expression profiling, robotic ISH screening and exhaustive shotgun NGS sequencebased transcriptome analysis, (now called RNA-seq)). In 2009, Professor Grimmond established Australia s International Cancer Genome Consortium program and is committed to sequencing the genomes, transcriptomes and methylomes of 500 pancreatic and ovarian cancer patients. This program is leading to new research efforts into systems-based analysis of cancer, cancer surveillance using personalised biomarkers and theranostics. Dr Suzanne Hill is a clinical pharmacologist, a former Associate Professor at the University of Newcastle and, the current Chair of Australia s Pharmaceutical Benefits Advisory Committee. This independent advisory committee assesses applications from drug companies and provides recommendations and advice to the Federal Health Minister on medicines that are suitable for listing on the government-subsidised Pharmaceutical Benefits Scheme. Prior to returning to Australia, Dr Hill worked for six years as a World Health Organisation (WHO) Scientist in the Geneva-based Department of Essential Medicines and Pharmaceutical Policies where she led the organisation s project on Better Medicines for Children which supported countries to provide simple, affordable access to medicines for children. From 2005, she was Secretary to the WHO Expert Committee on Essential Medicines (to determine the organisation s model list of medicines for adults and children) and was also chair of WHO s Guideline Review Committee which oversees the quality standards for WHO s guideline development. Dr Hill s research interests focus on the public health aspects of clinical pharmacology, particularly access to medicines and pharmacoeconomics. Her regulatory experience is long-standing. Before moving to Geneva and WHO, she was Associate Professor in Clinical Pharmacology, Faculty of Medicine and Health Sciences at the University of Newcastle, Australia and, as Director of the Newcastle Evaluation Group, helped provide pharmacoeconomic advice to the Pharmaceutical Benefits Advisory Committee of the day. Associate Professor Lisa Horvath is the Head of the Department of Medical Oncology, Royal Prince Alfred Hospital at the Sydney Cancer Centre and a Visiting Post-doctoral Scientist at the Garvan Institute for Medical Research. She is a clinical academic at both the University of Sydney and the University of New South Wales. She has an active clinical practice, is involved with a large number of clinical trials in prostate, lung and colorectal cancers in addition to phase I trial work. Associate Professor Horvath has published 35 original research papers in peer-reviewed journals in the last 13 years. She has also presented extensively at national and international meetings both peer-reviewed and invited presentations. During her PhD, Associate Professor Horvath s research was predominantly on tissue biomarkers of prognosis in localised prostate cancer, but since returning to clinical practice, her research has focused more on drug resistance in castrate-resistant prostate cancer. This work integrates clinical trial work and correlative biomarker studies using both standard and experimental anti-cancer treatments. This work has identified elevated plasma MIC-1, IL-4 and IL-6 as markers of docetaxel resistance in men with advanced prostate cancer. Furthermore, MIC-1 is a potential therapeutic target in vitro. Moreover, this biomarker project is part of a 5-year program funded by the Cancer Institute New South Wales, which aims to identify and develop new prognostic and predictive biomarkers in prostate cancer using a truly multidisciplinary approach to translational research. As Chair of the steering committee of PRIMe (Pharmacogenomic Research for Individualised Medicine), she is now involved in networking biomarker trials across New South Wales. This is a new initiative funded by the Cancer Council New South Wales. Dr Mustafa Khasraw is a consultant medical oncologist at the Andrew Love Cancer Centre in Geelong and Royal Melbourne Hospitals, Victoria. He is also a research fellow and a senior clinical lecturer at Deakin University, School of Medicine. After his medical oncology training at Royal North Shore Hospital in Sydney he undertook an oncology fellowship in the United States at Memorial Sloan-Kettering Cancer Centre in New York. Dr Khasraw is currently involved in a number of

19 National Speakers 19 collaborative research projects across different tumour streams. Dr Khasraw has published numerous manuscripts and book chapters and he acts regularly as a reviewer for a number of scientific journals. Associate Professor Matthew Links is a medical oncologist and medical educator based at St George Hospital in Sydney and con joint Associate Professor with the University of New South Wales. His medical interests are in lung cancer and innovation within postgraduate medical education. Associate Professor Links initiated the eviqed multiprofessional learning program for the Cancer Institute of New South Wales and is currently Director of Medical Oncology Advanced Training for South Eastern Sydney and Illawarra network and Lead clinician for Continuing Professional Development for the Adult Medicine Division of the Royal Australasian College of Physicians. Dr Sherene Loi is a medical oncologist specialised in the treatment of breast cancer patients. She leads the newly created Translational Breast Cancer Genomics laboratory as part of the Cancer Therapeutics program at the Peter MacCallum Cancer Centre in. The principal aim of her research is to translate scientific findings into innovative treatment approaches that may ultimately improve the clinical outcomes of breast cancer patients. Dr Loi returned to the Peter MacCallum Cancer Centre in 2013 after working in Brussels, Belgium (including a PhD and post-doctoral experience) at the Breast International Group clinical trial headquarters for eight years. There she gained significant experience in translational scientific research, development of novel targeted therapies, and the identification and validation of biomarkers that could potentially identify the population of breast cancer patients most likely to benefit from specific treatments. In particular, she has expertise in the application of genomic technologies such as gene expression microarrays and next generation sequencing technologies, and linking these genomic findings to early drug development using biomarker driven clinical trial designs. The main objective of this research is to identify the patients in whom certain drugs are most likely to be effective and therefore have the best benefit/toxicity ratio for that patient. She has been involved in the development, validation and assessment of clinical utility of the major prognostic gene signatures for early breast cancer, with a focus on Mammaprint and Genomic Grade (MapQuant ). Dr Loi has a particular interest in immunological aspects of breast cancer as well as understanding the molecular genetic heterogeneity of patients tumours and how this can affect survival and response to therapies. In addition to developing novel target therapies in certain subgroups, she has been involved in many of the major, practice changing adjuvant breast cancer trials in newly diagnosed HER2-overexpressing disease using anti-her2 therapy. These trials will and have recruited many thousands of patients world-wide, including Australia, and have led to a significant improvement in survival for women with this subtype of breast cancer. Dr Georgina Long is a clinical researcher and medical oncologist at the Melanoma Institute Australia, University of Sydney, Australia. She was a Fulbright Postdoctoral Scholar at Scripps Research Institute. She is an investigator on Phase I, II and III clinical trials in adjuvant and metastatic melanoma, and, with her colleagues at Westmead Hospital, spearheaded the investigation of BRAF inhibitor activity in the brain. Dr Long is chief investigator on National Health and Medical Research Council funded research into the molecular biology of melanoma, with a particular focus on clinical and biomarker correlates of systemic therapy sensitivity and resistance. Since commencing at the Melanoma Institute Australia in 2009, she has authored multiple publications in clinical and translational research in melanoma, and is a regular invited speaker at international conferences. Associate Professor Joe McKendrick is a medical oncologist and is Director of Oncology, Haematology and Palliative Care for Eastern Health in Victoria. He has a particular interest in lymphoma, colorectal cancer and urological malignancy, particularly testis cancer. He gained experience in the management of testis cancer at the University of Southamptom and the Cancer Research Campaign, Medical Oncology Unit in the United Kingdom. Associate Professor McKendrick also has an ongoing interest and involvement in

20 20 MOGA Annual Scientific Meeting clinical research and within the Eastern Health Oncology Research precinct, is principal investigator in a number of lymphoma, colorectal and genitourinary cancer trials. Associate Professor Michael MacManus is a radiation oncologist at the Peter MacCallum Cancer Centre, Melbourne specialising in lung cancer and haematological malignancies. He is also Associate Director (Research) in the Department of Radiation Oncology at the Peter MacCallum Cancer Centre. His research interests include the treatment of lung cancer with radiotherapy and chemoradiation, PET imaging of lung cancer and lymphomas, tumour hypoxia, metastasis and treatment of localised low grade lymphomas. Associate Professor MacManus has published more than 100 journal articles and has more than 3900 citations of his work. He is an internationally-recognised expert on PET imaging in oncology and has received many invitations to speak on the use of PET for staging, radiotherapy planning and response assessment, especially in lung cancer. He is a fellow of the International Cancer Imaging Society and has participated in the International Atomic Energy Authority (IAEA) international panel that made recommendations on the use of PET for radiotherapy planning. He is the principal investigator of several clinical trials, including the TROG/ALLG phase III trial in early stage follicular lymphoma. His recent work includes a collaboration with Associate Professor Olga Martin, leading to the development of a novel method for detecting circulating tumour cells in patients with lung cancer. Professor Grant McArthur is Director of the Skin and Melanoma Service at the Peter MacCallum Cancer Centre in Melbourne Australia. He is a Fellow of the Royal Australasian College of Physicians and holds a PhD in medical biology. He also is currently Head of Molecular Oncology and Translational Research Laboratories and Co-head of the Cancer Therapeutics Program and Assistant Executive Director of Research at the Peter MacCallum Cancer Centre. Professor McArthur is a previous recipient of the Translational Research Award of the Fondation Nelia et Amadeo Barletta and the Sir Edward Dunlop Clinical Cancer Research Fellowship of the Cancer Council of Victoria. He is national and international study chair or co-chair of a number of clinical trials in melanoma and Associate editor for melanoma of Annals of Oncology. He has extensive experience in communicating issues on the management and prevention of melanoma to lay audiences. Associate Professor Michael Michael graduated with honours in medicine from Monash University, and his medical oncology training was attained at the Peter MacCallum Cancer Centre. He was entered into the Fellowship of the Royal Australasian College of Physicians in 1995, followed by a further 12 months as a clinical fellow at the Centre. From , he was a Clinical Fellow to the Department of Medicine at the Princess Margaret Hospital at the Ontario Cancer Institute in Toronto, Canada, where he pursued his clinical and research interests in clinical pharmacology and gastrointestinal oncology. Associate Professor Michael returned to the in 1998 as to the Gastro- Intestinal (GI) and Thoracic Oncology Services. He is the current Director of the Upper GI Oncology Service and Co-Chair of the Neuroendocrine Unit at the. Associate Professor Michael s major research interests are Phase I and II trials of new drug entities and combinations and chemoradiation regimens in these malignancies, translating these into phase III studies through the cooperative trial groups. He also has a major interest in oncological clinical pharmacology, pharmacogenomics, tumoural cellular pharmacology and GI neuro-endocrine tumours. Associate Professor Michael is principal author or co-author of over 100 peer reviewed journal articles, invited reviews and chapters including presentations at several local and international conferences. He is a member of the Australian Gastro-intestinal Tumour Trials Group, Australian Lung Cancer Trials Group, Trans-Tasman Radiation Oncology Group, the GI and Lung Cancer Committees of the Cancer Council of Victoria, ASCO and ENETS. He was a member of the Australian Drug Evaluation Committee for the Therapeutic Goods Administration. He is also a Past Chairman ( ) and a current member of the Executive of the Medical Oncology Group of Australia, Chairing its Drug Issues Sub-committee.

21 National Speakers 21 Associate Professor Linda Mileshkin is a consultant medical oncologist at the Peter MacCallum, Cancer Centre and the Mercy Hospital for Women Melbourne, Australia and has a particular interest in the treatment of gynaecological cancers. Associate Professor Mileshkin is the Chair of the Special Advisory Committee-Medical Oncology, Royal Australasian College of Physicians. She is involved in multiple clinical research projects related to early and late phase studies of novel therapies for cancer and is an Associate Director for Cancer Trials Australia, and a member of the Board and Research Advisory Committee of the Australia New Zealand Gynaecological Oncology Group (ANZGOG). Associate Professor Mileshkin has expertise in running phase I-III trials, as well as the development and successful completion of several investigator-initiated phase II trials. Most recently she has made significant progress in the development and initiation of a cooperative group international phase III trial testing the role of adjuvant chemotherapy for cervical cancer. She also has a particular interest in the treatment of gynaecological and lung cancers, as well as carcinomas of unknown primary. Associate Professor Sandra O Toole is a tissue and molecular pathologist who divides her time between Royal Prince Alfred Hospital (RPAH) as a staff specialist and the Kinghorn Cancer Centre where she is Co-Head of Breast Translational Oncology. She is the founder and head of a new cutting edge diagnostic service at RPAH which offers comprehensive mutation profiling to guide cancer treatment. Associate Professor O Toole s research interests focus on novel therapeutic approaches in breast cancer and the molecular pathology of lung cancer. She has extensive experience in cancer biomarkers. Associate Professor Gary Richardson is Director of Oncology Clinics Victoria, Director of Cabrini Academic Haematology and Oncology Services and Associate Professor of medicine at Monash University, Australia. A well known medical oncologist, he is also Chairman of Foundation 49, a Men s Health Organisation sponsored by Cabrini Health, and the Private Cancer Physicians of Australia and, is part of the Federal Government advisory board that developed the National Male Health Policy and the Victorian Men s Health and Wellbeing Strategy. He undertook medical training at Monash University, completing his internship and residency at the Prince Henry s and St Vincent s Hospitals. This was followed by a fellowship in medical oncology at the Peter MacCallum Cancer Institute, Melbourne and the National Cancer Institute in Bethesda, Maryland, United States of America. Associate Professor Richardson s career path is distinguished by senior clinical and academic appointments in the United States and Australia. His clinical and research interests include: breast cancer, gynaecological oncology and lung cancer; targeted therapies; evidence-based treatment; men s health; risk factors and population based cancer screening, including genetic screening and new diagnostics. Associate Professor Clare Scott is a medical oncologist at the Royal Melbourne Hospital and the Royal Women s Hospital and Laboratory Head at the Walter and Eliza Hall Institute of Medical Research, studying drug resistance in ovarian cancer. Associate Professor Scott graduated in medicine from the University of Melbourne in 1989 and trained at the Royal Melbourne Hospital and the Peter MacCallum Cancer Clinic as a medical oncologist. She performed her PhD studies at the Walter and Eliza Hall Institute of Medical Research, studying the interactions of blood hormones and then studied drug resistance and apoptosis in mouse models of lymphoma. She furthered this work as a Special Fellow of the Leukemia and Lymphoma Society at the Cold Spring Harbor Laboratory on Long Island, New York. Associate Professor Scott has 15 years experience in clinical cancer genetics and in treating breast and ovarian cancer, in particular those that occur in clusters in families. She focuses on ovarian biology, including the role of apoptosis in infertility and on developing targeted therapies for ovarian cancer in novel xenograft mouse models. She has been awarded the Arnott Fellowship in Cancer Research by the Australasian College of Physicians (2000), the Seligson Cancer Fellowship at Cold Spring Harbor Laboratory (2003), the Burnet Prize from the Walter and Eliza Hall Institute of Medical Research (2009), the inaugural Cory Leadership Fellowship for Women in Science (WEHI, 2010), a Clinical Fellowship from the Victorian Cancer Agency (2011)

22 22 MOGA Annual Scientific Meeting and the Sir Edward Dunlop Cancer Research Fellow from the Cancer Council Victoria. Associate Professor David Thomas is a National Health Medical Research Council and Victorian Cancer Agency Senior Research Fellow. He is a medical oncologist specialising in sarcomas at the Peter MacCallum Cancer Centre, and a research fellow at the University of Melbourne. He serves on the editorial boards of several international journals, including Bioessays, the Japanese Journal of Orthopedic Research, Clinical Sarcoma Research, and Frontiers in Genetics. Associate Professor Thomas has a particular focus on the impact of genomics on cancer medicine. His current basic research interests include quantitative evolutionary genetics in cancer cell populations, mapping a cancer neochromosome at single nucleotide resolution, and understanding the role of the immune system in development of osteosarcoma. Based on the assumption that cancer genomics will create opportunities for placing human populations at the centre of cancer research, Associate Professor Thomas has played a key role in establishing several large-scale cancer cohorts. These include the world s largest cohort of sarcoma kindreds (the International Sarcoma Kindred Study), and Cancer 2015, a 10,000 strong cohort of newly diagnosed cancer patients drawn from all parts of the Victorian Cancer network. His work has impacted upon cancer care in several fields. Associate Professor Thomas was the lead author on a ground-breaking international clinical trial of denosumab in giant cell tumour of bone, which has led to a new therapeutic option for patients with advanced disease. He also established a national infrastructure for clinical research into sarcomas, having established the Australasian Sarcoma Study Group (ASSG) as its founding Chair ( ). The ASSG has recruited over 600 Australian patients with sarcoma to clinical studies since its inception. As Director of the statewide adolescent and young adult cancer service, ontrac@petermac ( ), he played a significant role in the development of adolescent and young adult (AYA) cancer services across the state, as well as nationally and internationally. In Victoria, AYA cancer care is now regarded as a standard of care. Convenor 2013 Blood, Biomarkers and Beyond Dr Yoland Antill is a medical oncologist at Cabrini Health and also consults at Frankston Hospital and Royal Melbourne Hospitals in Victoria. Dr Antill is the lead investigator for a number of local and international research studies and is involved in the development and conduct of clinical trials. She has published a number of research papers, abstracts, and book chapters many of which have been presented at local and international conferences. She is an invited member of the Victorian Clinical Oncology Groups for both the genetics and hereditary bowel groups as well as a member of the steering committee for the development of Breast Cancer Services at Cabrini Brighton. Dr Antill is a Fellow of the Royal Australasian College of Physicians. She trained at Royal North Shore Hospital in Sydney before completing a fellowship and doctoral studies at the in Melbourne. Dr Antill is a member of the Medical Oncology Group of Australia, the Clinical Oncological Society of Australia, the Australian Gynaecological Oncology Group, the Private Cancer Physicians of Australia and the American Society of Clinical Oncology. She is a former member of the executive committees for both the Medical Oncology Group of Australia and the kconfab Hereditary Breast Consortium.

23 Session Chairs 23 Session Chairs Dr Yoland Antill, Convenor ASM 2013 Medical Oncologist Cabrini Health Professor Frances Boyle AM Professor of Medical Oncology and Director, Patricia Ritchie Centre for Cancer Care and Research Mater Hospital Northern Clinical School of Medicine The University of Sydney Sydney, New South Wales Professor David Bowtell Head, Cancer Genomics and Genetics Program Principal Investigator, Australian Ovarian Cancer Study Department of Pathology and Department of Biochemistry The University of Melbourne Dr Martin Buck Mount Hospital Sir Charles Gairdner Hospital Perth, Western Australia Associate Professor Jacquie Chirgwin Box Hill and Maroondah Hospitals Director, Australia and New Zealand Breast Cancer Trials Group Professor Michael Green Director of Cancer Services Western Health Dr Andrew Haydon, Member ASM 2013 Planning Committee The Alfred Hospital Professor Grant McArthur Head, Translational Research Group and Head, Molecular Oncology Laboratory Associate Professor Michael Michael, Member ASM 2013 Planning Committee Director, Upper GI Oncology Service Co-Chair, Neuroendocrine Unit Associate Professor of Medicine University of Melbourne Associate Professor Linda Mileshkin Department of Medical Oncology and Haematology Mercy Hospital for Women Professor Michael Millward Cancer Council Professor of Clinical Cancer Research Head, Department of Medical Oncology Sir Charles Gairdner Hospital The University of Western Australia Director, Cancer Council Clinical Trials Western Australia Perth, Western Australia Professor Ian Olver AM Chief Executive Officer, Cancer Council Australia Sydney, New South Wales

24 24 MOGA Annual Scientific Meeting Professor H. Miles Prince Director, Centre for Blood Cell Therapies Director, Blood and Marrow Transplant Service Consultant Haematologist St Vincent s and Royal Melbourne Hospitals, Australian Red Cross Blood Service and Cabrini Hospital Department of Oncology Professor of Medicine The University of Melbourne and Monash University Associate Professor Gary Richardson, Member ASM 2013 Planning Committee Director, Oncology Clinics Victoria Director, Cabrini Academic Haematology and Oncology Services Dr Tess Schenberg, Member ASM 2013 Planning Committee MOGA National Advanced Trainee Representative The Alfred Hospital Associate Professor Benjamin Solomon, Member ASM 2013 Planning Committee Professor John R. Zalcberg OAM Chief Medical Officer and Executive Director Cancer Medicine